SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?
Identifieur interne : 000027 ( Main/Exploration ); précédent : 000026; suivant : 000028SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?
Auteurs : Saborni Chakraborty [États-Unis] ; Vamsee Mallajosyula [États-Unis] ; Cristina M. Tato [États-Unis] ; Gene S. Tan [États-Unis] ; Taia T. Wang [États-Unis]Source :
- Advanced drug delivery reviews [ 1872-8294 ] ; 2021.
Abstract
The ongoing SARS-CoV-2 pandemic has led to the focused application of resources and scientific expertise toward the goal of developing investigational vaccines to prevent COVID-19. The highly collaborative global efforts by private industry, governments and non-governmental organizations have resulted in a number of SARS-CoV-2 vaccine candidates moving to Phase III trials in a period of only months since the start of the pandemic. In this review, we provide an overview of the preclinical and clinical data on SARS-CoV-2 vaccines that are currently in Phase III clinical trials and in few cases authorized for emergency use. We further discuss relevant vaccine platforms and provide a discussion of SARS-CoV-2 antigens that may be targeted to increase the breadth and durability of vaccine responses.
DOI: 10.1016/j.addr.2021.01.014
PubMed: 33482248
PubMed Central: PMC7816567
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?</title><author><name sortKey="Chakraborty, Saborni" sort="Chakraborty, Saborni" uniqKey="Chakraborty S" first="Saborni" last="Chakraborty">Saborni Chakraborty</name><affiliation wicri:level="4"><nlm:affiliation>Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA</wicri:regionArea><placeName><region type="state">Californie</region><settlement type="city">Stanford (Californie)</settlement></placeName><orgName type="university">Université Stanford</orgName></affiliation></author><author><name sortKey="Mallajosyula, Vamsee" sort="Mallajosyula, Vamsee" uniqKey="Mallajosyula V" first="Vamsee" last="Mallajosyula">Vamsee Mallajosyula</name><affiliation wicri:level="4"><nlm:affiliation>Institute for Immunity, Transplantation, and Infection, Stanford University, Stanford, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Institute for Immunity, Transplantation, and Infection, Stanford University, Stanford, CA</wicri:regionArea><placeName><region type="state">Californie</region><settlement type="city">Stanford (Californie)</settlement></placeName><orgName type="university">Université Stanford</orgName></affiliation></author><author><name sortKey="Tato, Cristina M" sort="Tato, Cristina M" uniqKey="Tato C" first="Cristina M" last="Tato">Cristina M. Tato</name><affiliation wicri:level="2"><nlm:affiliation>Infectious Disease Initiative, Chan Zuckerberg Biohub, San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Infectious Disease Initiative, Chan Zuckerberg Biohub, San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Tan, Gene S" sort="Tan, Gene S" uniqKey="Tan G" first="Gene S" last="Tan">Gene S. Tan</name><affiliation wicri:level="2"><nlm:affiliation>J. Craig Venter Institute, 4120 Capricorn Lane, La Jolla, CA 92037, USA; Department of Infectious Diseases, University of California San Diego, La Jolla, CA 92037, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>J. Craig Venter Institute, 4120 Capricorn Lane, La Jolla, CA 92037, USA; Department of Infectious Diseases, University of California San Diego, La Jolla, CA 92037</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Wang, Taia T" sort="Wang, Taia T" uniqKey="Wang T" first="Taia T" last="Wang">Taia T. Wang</name><affiliation wicri:level="4"><nlm:affiliation>Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, USA; Department of Microbiology and Immunology, Stanford University, Stanford, CA, USA; Chan Zuckerberg Biohub, San Francisco, CA, USA. Electronic address: taiawang@stanford.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, USA; Department of Microbiology and Immunology, Stanford University, Stanford, CA, USA; Chan Zuckerberg Biohub, San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region><settlement type="city">Stanford (Californie)</settlement></placeName><orgName type="university">Université Stanford</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2021">2021</date><idno type="RBID">pubmed:33482248</idno><idno type="pmid">33482248</idno><idno type="doi">10.1016/j.addr.2021.01.014</idno><idno type="pmc">PMC7816567</idno><idno type="wicri:Area/Main/Corpus">000019</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000019</idno><idno type="wicri:Area/Main/Curation">000019</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000019</idno><idno type="wicri:Area/Main/Exploration">000019</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?</title><author><name sortKey="Chakraborty, Saborni" sort="Chakraborty, Saborni" uniqKey="Chakraborty S" first="Saborni" last="Chakraborty">Saborni Chakraborty</name><affiliation wicri:level="4"><nlm:affiliation>Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA</wicri:regionArea><placeName><region type="state">Californie</region><settlement type="city">Stanford (Californie)</settlement></placeName><orgName type="university">Université Stanford</orgName></affiliation></author><author><name sortKey="Mallajosyula, Vamsee" sort="Mallajosyula, Vamsee" uniqKey="Mallajosyula V" first="Vamsee" last="Mallajosyula">Vamsee Mallajosyula</name><affiliation wicri:level="4"><nlm:affiliation>Institute for Immunity, Transplantation, and Infection, Stanford University, Stanford, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Institute for Immunity, Transplantation, and Infection, Stanford University, Stanford, CA</wicri:regionArea><placeName><region type="state">Californie</region><settlement type="city">Stanford (Californie)</settlement></placeName><orgName type="university">Université Stanford</orgName></affiliation></author><author><name sortKey="Tato, Cristina M" sort="Tato, Cristina M" uniqKey="Tato C" first="Cristina M" last="Tato">Cristina M. Tato</name><affiliation wicri:level="2"><nlm:affiliation>Infectious Disease Initiative, Chan Zuckerberg Biohub, San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Infectious Disease Initiative, Chan Zuckerberg Biohub, San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Tan, Gene S" sort="Tan, Gene S" uniqKey="Tan G" first="Gene S" last="Tan">Gene S. Tan</name><affiliation wicri:level="2"><nlm:affiliation>J. Craig Venter Institute, 4120 Capricorn Lane, La Jolla, CA 92037, USA; Department of Infectious Diseases, University of California San Diego, La Jolla, CA 92037, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>J. Craig Venter Institute, 4120 Capricorn Lane, La Jolla, CA 92037, USA; Department of Infectious Diseases, University of California San Diego, La Jolla, CA 92037</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Wang, Taia T" sort="Wang, Taia T" uniqKey="Wang T" first="Taia T" last="Wang">Taia T. Wang</name><affiliation wicri:level="4"><nlm:affiliation>Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, USA; Department of Microbiology and Immunology, Stanford University, Stanford, CA, USA; Chan Zuckerberg Biohub, San Francisco, CA, USA. Electronic address: taiawang@stanford.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, USA; Department of Microbiology and Immunology, Stanford University, Stanford, CA, USA; Chan Zuckerberg Biohub, San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region><settlement type="city">Stanford (Californie)</settlement></placeName><orgName type="university">Université Stanford</orgName></affiliation></author></analytic><series><title level="j">Advanced drug delivery reviews</title><idno type="eISSN">1872-8294</idno><imprint><date when="2021" type="published">2021</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The ongoing SARS-CoV-2 pandemic has led to the focused application of resources and scientific expertise toward the goal of developing investigational vaccines to prevent COVID-19. The highly collaborative global efforts by private industry, governments and non-governmental organizations have resulted in a number of SARS-CoV-2 vaccine candidates moving to Phase III trials in a period of only months since the start of the pandemic. In this review, we provide an overview of the preclinical and clinical data on SARS-CoV-2 vaccines that are currently in Phase III clinical trials and in few cases authorized for emergency use. We further discuss relevant vaccine platforms and provide a discussion of SARS-CoV-2 antigens that may be targeted to increase the breadth and durability of vaccine responses.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">33482248</PMID><DateRevised><Year>2021</Year><Month>01</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-8294</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2021</Year><Month>Jan</Month><Day>20</Day></PubDate></JournalIssue><Title>Advanced drug delivery reviews</Title><ISOAbbreviation>Adv Drug Deliv Rev</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S0169-409X(21)00024-7</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.addr.2021.01.014</ELocationID><Abstract><AbstractText>The ongoing SARS-CoV-2 pandemic has led to the focused application of resources and scientific expertise toward the goal of developing investigational vaccines to prevent COVID-19. The highly collaborative global efforts by private industry, governments and non-governmental organizations have resulted in a number of SARS-CoV-2 vaccine candidates moving to Phase III trials in a period of only months since the start of the pandemic. In this review, we provide an overview of the preclinical and clinical data on SARS-CoV-2 vaccines that are currently in Phase III clinical trials and in few cases authorized for emergency use. We further discuss relevant vaccine platforms and provide a discussion of SARS-CoV-2 antigens that may be targeted to increase the breadth and durability of vaccine responses.</AbstractText><CopyrightInformation>Copyright © 2021. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chakraborty</LastName><ForeName>Saborni</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mallajosyula</LastName><ForeName>Vamsee</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Institute for Immunity, Transplantation, and Infection, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tato</LastName><ForeName>Cristina M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Infectious Disease Initiative, Chan Zuckerberg Biohub, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Gene S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>J. Craig Venter Institute, 4120 Capricorn Lane, La Jolla, CA 92037, USA; Department of Infectious Diseases, University of California San Diego, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Taia T</ForeName><Initials>TT</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, USA; Department of Microbiology and Immunology, Stanford University, Stanford, CA, USA; Chan Zuckerberg Biohub, San Francisco, CA, USA. Electronic address: taiawang@stanford.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Adv Drug Deliv Rev</MedlineTA><NlmUniqueID>8710523</NlmUniqueID><ISSNLinking>0169-409X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">ORF3a</Keyword><Keyword MajorTopicYN="N">Phase III vaccine trials</Keyword><Keyword MajorTopicYN="N">Pre-fusion S protein</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 vaccine</Keyword><Keyword MajorTopicYN="N">Vaccine platform</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors have no competing interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>01</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>01</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>22</Day><Hour>20</Hour><Minute>9</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33482248</ArticleId><ArticleId IdType="pii">S0169-409X(21)00024-7</ArticleId><ArticleId IdType="doi">10.1016/j.addr.2021.01.014</ArticleId><ArticleId IdType="pmc">PMC7816567</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li></region><settlement><li>Stanford (Californie)</li></settlement><orgName><li>Université Stanford</li></orgName></list><tree><country name="États-Unis"><region name="Californie"><name sortKey="Chakraborty, Saborni" sort="Chakraborty, Saborni" uniqKey="Chakraborty S" first="Saborni" last="Chakraborty">Saborni Chakraborty</name></region><name sortKey="Mallajosyula, Vamsee" sort="Mallajosyula, Vamsee" uniqKey="Mallajosyula V" first="Vamsee" last="Mallajosyula">Vamsee Mallajosyula</name><name sortKey="Tan, Gene S" sort="Tan, Gene S" uniqKey="Tan G" first="Gene S" last="Tan">Gene S. Tan</name><name sortKey="Tato, Cristina M" sort="Tato, Cristina M" uniqKey="Tato C" first="Cristina M" last="Tato">Cristina M. Tato</name><name sortKey="Wang, Taia T" sort="Wang, Taia T" uniqKey="Wang T" first="Taia T" last="Wang">Taia T. Wang</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidStanfordV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000027 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000027 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidStanfordV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:33482248
|texte= SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:33482248" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidStanfordV1
| This area was generated with Dilib version V0.6.38. |  |